Q32 Bio has filed a prospectus with the U.S. Securities and Exchange Commission (SEC) regarding a proposed offering amounting to $300M. The filing provides the regulatory framework for the company to issue securities, outlining the intended use of proceeds and the structure of the deal.

The prospectus submission is a necessary step for the company to access capital markets. It includes financial statements, risk factors, and details about the business operations that potential investors will review before participating in the offering.

The $300M figure represents the target size of the offering, though the final amount raised may vary based on market conditions and investor demand. The securities being offered are subject to approval by the SEC before they can be sold to the public.